In Vivo Albumin-Binding of a C-Functionalized Cyclam Platform for 64Cu-PET/CT Imaging in Breast Cancer Model

In the aim to design small molecules capable of binding in vivo to albumin to form bioconjugates, a second generation GluCAB derivative(Glucose-Chelator-Albumin Bioconjugate) has been synthesized and studied for in vivo 64 Cu-PET/CT imaging in breast cancer mice models together with its first-generation analogue. This series of radioligands - also capable of complexing therapeutic isotopes and therefore classified as theranostic agents - are working on the principle of tumor targeting through the Enhanced Permeability and Retention (EPR) effect as well as glucose metabolism.